Home
Webinar registration: Completion of the Pediatric Praziquantel Consortium’s pivotal Phase III trial
Join us as we celebrate a major achievement for the Pediatric Praziquantel Consortium: completion of the pivotal clinical Phase III trial of arpraziquantel – a potential new treatment option for the estimated 50 million preschool-aged children with schistosomiasis.
Date: Wednesday 8 December 2021
Time: 13:00-15:00 (CET)
Agenda
| Presenter/Moderator | Topic | Time | |
|---|---|---|---|
| 1. | Bert Leufkens, Pediatric Praziquantel Consortium Board member and Scientific Lead, Lygature | Welcome and introduction | 13:00-13:15 |
| 2. | Peter Guenter, Member of the Executive Board of Merck and CEO Healthcare | Keynote address via video message: Harnessing the power of innovation and partnership to eliminate schistosomiasis | 13:15-13:20 |
| 3. | Jutta Reinhard-Rupp, Head of the Global Health Institute at Merck, and Pediatric Praziquantel Consortium Board Chair | The Pediatric Praziquantel Consortium: Its history and journey to success | 13:20-13:35 |
| 4. | Benjamin Dälken, Senior Director, Global Program Lead Immunology & Global Health at Merck | Results of the Pivotal Clinical Phase III Study | 13:35-13:50 |
| 5. | Eliézer Kouakou N’Goran, Côte d’Ivoire Principal Investigator | Clinical trial experiences in Côte d’Ivoire | 13:50-14:00 |
| 6. | To be confirmed | To be confirmed | 14:00-14:10 |
| 7. | Peter Steinmann, Co-lead of the Consortium Access sub-team, Swiss TPH | The Pediatric Praziquantel Consortium ADOPT Program | 14:10-14:20 |
| 8. | Bert Leufkens, Pediatric Praziquantel Consortium Board member and Scientific Lead, Lygature | Q&A with questions from audience | 14:20-14:40 |
| 9. | Michael Makanga, CEO of EDCTP | Closing remarks | 14:40-14:45 |
Please register for this webinar by completing the form below. After registering you will receive a confirmation e-mail with a link to the webinar.
Please remember to check your spam folder if you do not receive an e-mail confirmation.
For questions regarding registration, feel free to contact the Pediatric Praziquantel Consortium at: info@pediatricpraziquantelconsortium.org